HCMC University Medical Centre and Novartis Strengthen Medical Collaboration
2025–2027 agreement aims to advance innovation, research, and professional training
On November 19, in Ho Chi Minh City, the University Medical Centre of Hồ Chí Minh City (UMC) and Novartis Vietnam Ltd. signed a Memorandum of Understanding (MoU) for the 2025–2027 period. This agreement reinforces a long-term partnership that was first established in 2021.
The core objectives of the agreement are to foster medical innovation, expand clinical research capabilities, and strengthen healthcare workforce training, with the goal of improving patient outcomes in Việt Nam. Associate Professor Dr. Nguyễn Hoàng Định, Vice Director of UMC, indicated that the collaboration contributes to expanding the hospital’s network of strategic partners, bringing new opportunities in training and treatment, and helping to realize the vision of innovative medicine for patient health.
The partnership outlined in the MoU concentrates on four key areas: developing and expanding the Centre of Excellence model, enhancing healthcare professionals’ capabilities, advancing clinical research cooperation according to international standards, and expanding patient-oriented programs.
Moving forward from 2025, Novartis and UMC will continue to expand their partnership across core areas, including treatment enhancement, professional education, and clinical research. Ongoing initiatives include the UMC Health Project for transplant patients, the Lipid Control Centre Project, and the SpA Optimal Management Program for patients with axial spondylarthritis. Medical education collaboration will also be strengthened through the Education Partnership Programme, the Continuous Medical Education Programme, clinical pharmacy training, and patient education.
In parallel, UMC and Novartis will participate in Novartis Global Trials, with six ongoing clinical studies in Việt Nam focusing on innovative therapies, aiming to provide Vietnamese patients with advanced treatment options and improved quality of life. Jondy Syjuco, Country President of Novartis Vietnam, expressed confidence that combining Novartis’ global research strength with leading hospitals will advance clinical research, strengthen medical capacity, and enable patients in Việt Nam to access high-quality therapies sooner.
